Home › Baxter BioScience Announces Positive Phase III Results For BAX 817, Investigational Recombinant Treatment For Hemophilia A And B Patients With Inhibitors
 

Keywords :   


Baxter BioScience Announces Positive Phase III Results For BAX 817, Investigational Recombinant Treatment For Hemophilia A And B Patients With Inhibitors

2015-04-01 07:33:48| drugdiscoveryonline Home Page

Baxter International Inc. recently announced positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an investigational recombinant factor VIIa (rFVIIa) treatment for people with hemophilia A or B who develop inhibitors

Tags: with results iii positive

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
14.05Nu Skin Releases 2023 Social Impact and Sustainability Report
14.05P&G Unveils Plans to Feature Brands During the Olympic and Paralympic Games Paris 2024
14.05The LOccitane Group Appoints Evelyne LY-Wainer Managing Director Global Travel Retail
14.05Recovery resources available for Texas livestock producers
14.05About-Face and AF94 Appoint Francesca Raminella as New CEO
14.05An unraveled genetic mystery in Angus
14.05Is HPAI a risk to beef cattle?
14.05Fresh Partners with Juno Shen on Limited-Edition Kombucha Facial Treatment Essence
More »